MARKET

SVRA

SVRA

Savara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.770
0.000
0.00%
Opening 13:54 01/22 EST
OPEN
1.740
PREV CLOSE
1.770
HIGH
1.790
LOW
1.720
VOLUME
190.57K
TURNOVER
--
52 WEEK HIGH
3.590
52 WEEK LOW
0.9952
MARKET CAP
95.81M
P/E (TTM)
-1.3258
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Simply Wall St. · 1d ago
8-K: Savara Inc
(EDGAR Online via COMTEX) -- Savara Inc false 0001160308 0001160308 2021-01-15 2021-01-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
Is SVRA A Good Stock To Buy Now?
Insider Monkey · 12/10/2020 17:02
Immutep, Greenwich LifeSciences leads healthcare gainers; Xenetic Biosciences, Oncternal Therapeutics among major losers
Gainers: Immutep (IMMP) +204%, Greenwich LifeSciences (GLSI) +60%, TG Therapeutics (TGTX) +37%, SELLAS Life Sciences (SLS) +28%, Anixa Biosciences (ANIX) +18%.Losers: Xenetic Biosciences (XBIO) -32%, Oncternal Therapeutics (ONCT)-26%, GeoVax Labs (GOVX) -26%, Genetic Technologies (GENE) -20%, Savara (SVRA) -10%.
Seekingalpha · 12/10/2020 16:00
Savara's AeroVanc flunks in late-stage study in cystic fibrosis with MRSA infection, development discontinued
Savara (SVRA) plummets 26% in premarket in reaction to topline data from the Phase 3 AVAIL study evaluating AeroVanc (vancomycin hydrochloride inhalation powder) in cystic fibrosis patients with methicillin-resistant Staphylococcus aureus ((MRSA))
Seekingalpha · 12/10/2020 13:59
Savara Provides Pipeline And Business Update; Co. Discontinues Development Of Apulmiq Program, Focuses Resources On Molgradex In aPAP, Reduces Operating Expenses 'to Align with Streamlined Development Programs'
Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operating Expenses
Benzinga · 12/10/2020 13:10
Savara Provides Pipeline and Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPA...
Business Wire · 12/10/2020 13:05
Savara Provides Pipeline and Business Update
--Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO
BusinessWire · 12/10/2020 10:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SVRA. Analyze the recent business situations of Savara through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SVRA stock price target is 2.667 with a high estimate of 3.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 129
Institutional Holdings: 30.03M
% Owned: 55.48%
Shares Outstanding: 54.13M
TypeInstitutionsShares
Increased
13
455.69K
New
21
6.84K
Decreased
28
2.96M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+0.77%
Key Executives
Chairman/Chief Executive Officer/Director
Matthew Pauls
Chief Financial Officer/Secretary
David Lowrance
Other
Badrul Chowdhury
Independent Director
Nevan Elam
Independent Director
Richard Hawkins
Independent Director
Joseph McCracken
Independent Director
David Ramsay
Independent Director
Ricky Sun
Independent Director
Annigje van Es-Johansson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SVRA
Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.
More

Webull offers kinds of Savara Inc stock information, including NASDAQ:SVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SVRA stock methods without spending real money on the virtual paper trading platform.